home / stock / femy / femy news

FEMY News and Press, Femasys Inc. From 11/10/22

Stock Information
Company Name: Femasys Inc.
Stock Symbol: FEMY
Market: NASDAQ
Website: femasys.com
Menu
FEMY FEMY Quote FEMY Short FEMY News FEMY Articles FEMY Message Board
Get FEMY Alerts

News, Short Squeeze, Breakout and More Instantly...
FEMY - Femasys Inc. Announces Financial Results for the Third Quarter Ended September 30, 2022 and Provides Corporate Update

--FemaSeed ® de novo trial enrollment accelerates with strategic trial design update to focus on male factor infertility-- -- Company remains on track to file an Investigational Device Exemption (IDE) for a pivotal trial to support a Pre-Market Authorization...
FEMY - Femasys Inc. Provides Strategic Update on its FemaSeed® Pivotal Trial Design to Expedite Clinical Program Advancement

- Updated FemaSeed ® LOCAL artificial insemination trial design focuses on male factor infertility in patient trial recruitment, with a goal of achieving accelerated enrollment - ATLANTA, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical comp...

FEMY - Femasys to Participate in 78th Annual American Society for Reproductive Medicine (ASRM) Scientific Congress

ATLANTA, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women’s needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, today announced that the Co...

FEMY - Femasys Inc. Announces the Appointment of Christine Thomas as Senior Vice President of Regulatory and Clinical Affairs

ATLANTA, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women’s needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, today announced the appoint...
FEMY - Femasys Inc. Announces Enrollment Completion for Stage 2 Study of FemBloc for Permanent Birth Control

ATLANTA, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, today announced enrollment complet...

FEMY - Femasys commercially launches Femcerv for cervical cancer screening

Femasys ( NASDAQ: FEMY ) said its endocervical tissue sampler, FemCerv, was commercially available now. The Company also appointed Michael Meier as Vice President of Sales and Marketing. FemCerv is used to capture and protect a comprehensive 360-degr...

FEMY - Femasys Inc. Announces the Commercial Availability of FemCerv® for Cervical Cancer Screening and Expands Management Team

- FemCerv ® is the first endocervical tissue sampler designed to improve tissue quality and quantity that is expected to be an improvement over the existing standard of care - - Company expands management team with the hiring of a sales and marketing executive to ...
FEMY - Femasys Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference

ATLANTA, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, today announced that the Kathy Le...

FEMY - Femasys (FEMY) Investor Presnetation - Slideshow

The following slide deck was published by Femasys Inc. in conjunction with this event. For further details see: Femasys (FEMY) Investor Presnetation - Slideshow

FEMY - Femasys GAAP EPS of -$0.22 beats by $0.01, revenue of $0.3M misses by $0.01M

Femasys press release ( NASDAQ: FEMY ): Q2 GAAP EPS of -$0.22 beats by $0.01 . Revenue of $0.3M (-6.3% Y/Y) misses by $0.01M . Cash and cash equivalents as of June 30, 2022 and December 31, 2021, were $19,116,419 and $24,783,029, respectively. For further...
Previous 10 Next 10